BACKGROUND & AIMS: Lysophosphatidic acid (LPA) is a potent inducer of colon cancer and LPA receptor type 2 (LPA(2)) is overexpressed in colon tumors. LPA(2) interacts with membrane-associated guanylate kinase with inverted orientation-3 (MAGI-3) and the Na+/H+ exchanger regulatory factor 2 (NHERF-2), but the biological effects of these interactions are unknown. We investigated the roles of MAGI-3 and NHERF-2 in LPA(2)-mediated signaling in human colon cancer cells. METHODS: We overexpressed or knocked down MAGI-3 in HCT116 and SW480 cells. The effects of MAGI-3 and NHERF-2 in LPA-induced cell migration, invasion, inositol phosphate generation, and nuclear factor-κB activation were determined. Expression of MAGI-3 and NHERF-2 in human colon tumor tissues was analyzed using tissue microarray analysis. RESULTS: NHERF-2 promoted migration and invasion of colon cancer cells, whereas MAGI-3 inhibited these processes. MAGI-3 competed with NHERF-2 for binding to LPA(2) and phospholipase C-β3. However, NHERF-2 and MAGI-3 reciprocally regulated LPA(2)-induced phospholipase C activity. MAGI-3 increased the interaction of LPA(2) with Gα(12), whereas NHERF-2 preferentially promoted interaction between LPA(2) and Gα(q). MAGI-3 decreased the tumorigenic capacity of LPA(2) by attenuating the activities of nuclear factor-κB and c-Jun N-terminal kinase. MAGI-3 and NHERF-2 were expressed differentially in colon adenocarcinomas, consistent with their opposing effects. CONCLUSIONS: LPA(2) is dynamically regulated by 2 distinct PDZ proteins via modulation of G-protein coupling and receptor signaling. MAGI-3 is a negative regulator of LPA(2) signaling.
BACKGROUND & AIMS:Lysophosphatidic acid (LPA) is a potent inducer of colon cancer and LPA receptor type 2 (LPA(2)) is overexpressed in colon tumors. LPA(2) interacts with membrane-associated guanylate kinase with inverted orientation-3 (MAGI-3) and the Na+/H+ exchanger regulatory factor 2 (NHERF-2), but the biological effects of these interactions are unknown. We investigated the roles of MAGI-3 and NHERF-2 in LPA(2)-mediated signaling in humancolon cancer cells. METHODS: We overexpressed or knocked down MAGI-3 in HCT116 and SW480 cells. The effects of MAGI-3 and NHERF-2 in LPA-induced cell migration, invasion, inositol phosphate generation, and nuclear factor-κB activation were determined. Expression of MAGI-3 and NHERF-2 in humancolon tumor tissues was analyzed using tissue microarray analysis. RESULTS:NHERF-2 promoted migration and invasion of colon cancer cells, whereas MAGI-3 inhibited these processes. MAGI-3 competed with NHERF-2 for binding to LPA(2) and phospholipase C-β3. However, NHERF-2 and MAGI-3 reciprocally regulated LPA(2)-induced phospholipase C activity. MAGI-3 increased the interaction of LPA(2) with Gα(12), whereas NHERF-2 preferentially promoted interaction between LPA(2) and Gα(q). MAGI-3 decreased the tumorigenic capacity of LPA(2) by attenuating the activities of nuclear factor-κB and c-Jun N-terminal kinase. MAGI-3 and NHERF-2 were expressed differentially in colon adenocarcinomas, consistent with their opposing effects. CONCLUSIONS:LPA(2) is dynamically regulated by 2 distinct PDZ proteins via modulation of G-protein coupling and receptor signaling. MAGI-3 is a negative regulator of LPA(2) signaling.
Authors: Sami R Fam; Maryse Paquet; Amanda M Castleberry; Heide Oller; C Justin Lee; Stephen F Traynelis; Yoland Smith; C Chris Yun; Randy A Hall Journal: Proc Natl Acad Sci U S A Date: 2005-05-18 Impact factor: 11.205
Authors: C Chris Yun; Hong Sun; Dongsheng Wang; Raluca Rusovici; Amanda Castleberry; Randy A Hall; Hyunsuk Shim Journal: Am J Physiol Cell Physiol Date: 2005-02-23 Impact factor: 4.249
Authors: Huanchun Zhang; Agnieszka Bialkowska; Raluca Rusovici; Sengthong Chanchevalap; Hyunsuk Shim; Jonathan P Katz; Vincent W Yang; C Chris Yun Journal: J Biol Chem Date: 2007-04-12 Impact factor: 5.157
Authors: Elizabeth Buck; Alexandra Eyzaguirre; Sharon Barr; Stuart Thompson; Regina Sennello; David Young; Kenneth K Iwata; Neil W Gibson; Pablo Cagnoni; John D Haley Journal: Mol Cancer Ther Date: 2007-02 Impact factor: 6.261
Authors: Stefanie Klemm; Stephanie Zimmermann; Christian Peschel; Tak W Mak; Jürgen Ruland Journal: Proc Natl Acad Sci U S A Date: 2006-11-09 Impact factor: 11.205
Authors: Y Xu; D C Gaudette; J D Boynton; A Frankel; X J Fang; A Sharma; J Hurteau; G Casey; A Goodbody; A Mellors Journal: Clin Cancer Res Date: 1995-10 Impact factor: 12.531
Authors: Juncheng Dai; Mingtao Huang; Christopher I Amos; Rayjean J Hung; Adonina Tardon; Angeline Andrew; Chu Chen; David C Christiani; Demetrius Albanes; Gadi Rennert; Jingyi Fan; Gary Goodman; Geoffrey Liu; John K Field; Kjell Grankvist; Lambertus A Kiemeney; Loic Le Marchand; Matthew B Schabath; Mattias Johansson; Melinda C Aldrich; Mikael Johansson; Neil Caporaso; Philip Lazarus; Stephan Lam; Stig E Bojesen; Susanne Arnold; Maria Teresa Landi; Angela Risch; H-Erich Wichmann; Heike Bickeboller; Paul Brennan; Sanjay Shete; Olle Melander; Hans Brunnstrom; Shan Zienolddiny; Penella Woll; Victoria Stevens; Zhibin Hu; Hongbing Shen Journal: Int J Cancer Date: 2019-10-31 Impact factor: 7.396
Authors: Sei-Jung Lee; Yi Ran No; Duyen T Dang; Long H Dang; Vincent W Yang; Hyunsuk Shim; C Chris Yun Journal: J Biol Chem Date: 2013-07-23 Impact factor: 5.157